Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.23 HKD | +1.95% | 0.00% | -21.23% |
May. 02 | Alphamab Oncology's 2023 Loss Narrows as Revenue Rises | MT |
Apr. 10 | Alphamab Oncology Presents Phase-I Clinical Trial Results at 2024 AACR Annual Meeting | MT |
Evolution of the average Target Price on Alphamab Oncology
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Alphamab Oncology
UBS | |
Nomura |
EPS Revisions
- Stock Market
- Equities
- 9966 Stock
- Consensus Alphamab Oncology